Literature DB >> 32062679

Is it safe and effective to maintain the vaginal pessary without removing it for 2 consecutive years?

Alessio Miceli1, Manuel Fernández-Sánchez1,2, Juan Polo-Padillo3, José-Luis Dueñas-Díez4,5,6.   

Abstract

INTRODUCTION AND HYPOTHESIS: The study was aimed at evaluating the safety and efficacy of ring pessaries without support under continuous use without periodic removal or replacement for the treatment of advanced pelvic organ prolapse (POP) in women for 2 consecutive years.
METHODS: This study was a prospective observational study. A total of 123 women were recruited in a tertiary hospital from January 2013 to January 2016. The primary objective was the percentage of patients maintaining the use of the pessary after 24 months. The secondary objectives were the reasons for discontinuation and the adverse events in patients with successful fittings.
RESULTS: A total of 115 patients (93.5%) had a successful fitting. Four patients died of non-pessary-related causes during the study and, one patient dropped out the follow-up so that finally, 110 patients were included in the efficacy analysis. Pessary use was maintained by 91.8% of the women at the end of the study. The adverse events rate was low (27.0%). The two main factors of interruption in the pessary use were: age (OR 0.93; 95% CI 0.87-0.99) and history of urinary urge incontinence (OR 0.33; 95% CI 0.11-0.96]).
CONCLUSIONS: A high success rate and low adverse events rate were achieved in patients with advanced-stage POP with continuous pessary use for 24 months, indicating that a ring pessary could also be used without periodic removal for at least the first 2 years. This practice could reduce the number of control visits.

Entities:  

Keywords:  Advanced POP; Continuous use; Efficacy; Ring pessary without support; Safety

Mesh:

Year:  2020        PMID: 32062679     DOI: 10.1007/s00192-020-04240-5

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  23 in total

1.  A survey of pessary use by members of the American urogynecologic society.

Authors:  G W Cundiff; A C Weidner; A G Visco; R C Bump; W A Addison
Journal:  Obstet Gynecol       Date:  2000-06       Impact factor: 7.661

2.  Ring pessary for all pelvic organ prolapse.

Authors:  Tarinee Manchana
Journal:  Arch Gynecol Obstet       Date:  2010-09-17       Impact factor: 2.344

3.  The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction.

Authors:  R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith
Journal:  Am J Obstet Gynecol       Date:  1996-07       Impact factor: 8.661

4.  Pelvic organ prolapse.

Authors:  Anne M Weber; Holly E Richter
Journal:  Obstet Gynecol       Date:  2005-09       Impact factor: 7.661

5.  Current management of pelvic organ prolapse in aging women: EMAS clinical guide.

Authors:  Andrea Giannini; Eleonora Russo; Antonio Cano; Peter Chedraui; Dimitrios G Goulis; Irene Lambrinoudaki; Patrice Lopes; Gita Mishra; Alfred Mueck; Margaret Rees; Levent M Senturk; John C Stevenson; Petra Stute; Pauliina Tuomikoski; Tommaso Simoncini
Journal:  Maturitas       Date:  2018-02-06       Impact factor: 4.342

6.  The distribution of pelvic organ support in a population of female subjects seen for routine gynecologic health care.

Authors:  S E Swift
Journal:  Am J Obstet Gynecol       Date:  2000-08       Impact factor: 8.661

7.  Successful use of ring pessary with support for advanced pelvic organ prolapse.

Authors:  Jing Ding; Chun Chen; Xiao-Chen Song; Lei Zhang; Mou Deng; Lan Zhu
Journal:  Int Urogynecol J       Date:  2015-05-16       Impact factor: 2.894

Review 8.  Female pelvic organ prolapse using pessaries: systematic review.

Authors:  Suelene Costa de Albuquerque Coelho; Edilson Benedito de Castro; Cássia Raquel Teatin Juliato
Journal:  Int Urogynecol J       Date:  2016-03-18       Impact factor: 2.894

9.  How often should shelf/Gellhorn pessaries be changed? A survey of IUGA urogynaecologists.

Authors:  A Khaja; R M Freeman
Journal:  Int Urogynecol J       Date:  2014-02-15       Impact factor: 2.894

10.  Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity.

Authors:  Susan L Hendrix; Amanda Clark; Ingrid Nygaard; Aaron Aragaki; Vanessa Barnabei; Anne McTiernan
Journal:  Am J Obstet Gynecol       Date:  2002-06       Impact factor: 8.661

View more
  5 in total

1.  Cross sectional study on assessment of ring pessary cleaning and removal every six months: adverse events and complications.

Authors:  Suelene Costa de Albuquerque Coelho; Gláucia Miranda Varella Pereira; Luiz Gustavo Oliveira Brito; Cássia Raquel Teatin Juliato
Journal:  Int Urogynecol J       Date:  2021-04-08       Impact factor: 2.894

Review 2.  A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence.

Authors:  Cara L Grimes; Ethan M Balk; Catrina C Crisp; Danielle D Antosh; Miles Murphy; Gabriela E Halder; Peter C Jeppson; Emily E Weber LeBrun; Sonali Raman; Shunaha Kim-Fine; Cheryl Iglesia; Alexis A Dieter; Ladin Yurteri-Kaplan; Gaelen Adam; Kate V Meriwether
Journal:  Int Urogynecol J       Date:  2020-04-27       Impact factor: 2.894

3.  The impact on complication rates of delayed routine pessary reviews during the COVID-19 pandemic.

Authors:  Esther R McNeill; James Lucocq; Kirsty Brown; Vanessa Kay
Journal:  Int Urogynecol J       Date:  2022-08-30       Impact factor: 1.932

4.  Pessaries and rectovaginal fistulae: consequences of delayed clinical follow-up in the Covid-19 pandemic.

Authors:  Jordan Mendelson; Bogdan Grigorescu; Catherine Quinn; George Lazarou
Journal:  Int Urogynecol J       Date:  2021-07-08       Impact factor: 2.894

5.  Adapting to Challenging Circumstances: Pessary Care in a Racially Diverse Urban Population Within a U.S. Epicenter of the COVID-19 Pandemic.

Authors:  Priyanka Kadam Halani; Eden Gelman; Yvette Duchein; Nicole Roselli; Ava Leegant
Journal:  Female Pelvic Med Reconstr Surg       Date:  2022-02-01       Impact factor: 2.091

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.